Our recent study showed that a hydrogel co-loaded with the TLR7 agonists imiquimod and ropivacaine increased the infiltration of CD8+T cells into the residual tumor tissues to prevent tumor recurrence [66]. The gene discussed is CD8A; the disease is neoplasm.